Log In
BCIQ
Print this Print this
 

GS-0976 (formerly NDI-010976)

  Manage Alerts
Collapse Summary General Information
Company Gilead Sciences Inc.
DescriptionAllosteric acetyl-coenzyme A carboxylase (ACAC; ACC) inhibitor
Molecular Target Acetyl-Coenzyme A carboxylase (ACAC) (ACC)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationNon-alcoholic steatohepatitis (NASH)
Indication DetailsTreat non-alcoholic steatohepatitis (NASH); Treat non-alcoholic steatohepatitis (NASH) and fatty liver disease-spectrum disorders
Regulatory Designation U.S. - Fast Track (Treat non-alcoholic steatohepatitis (NASH))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,200.0M

$400.0M

$800.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/04/2016

$1,200.0M

$400.0M

$800.0M

Get a free BioCentury trial today